Cargando…
Sodium-glucose co-transporter-2 inhibitors and euglycemic ketoacidosis: Wisdom of hindsight
Sodium-glucose co-transporter-2 inhibitors (SGLT-2i) are newly approved class of oral anti-diabetic drugs, in the treatment of type 2 diabetes, which reduces blood glucose through glucouresis via the kidney, independent, and irrespective of available pancreatic beta-cells. Studies conducted across t...
Autor principal: | Singh, Awadhesh Kumar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673799/ https://www.ncbi.nlm.nih.gov/pubmed/26693421 http://dx.doi.org/10.4103/2230-8210.167554 |
Ejemplares similares
-
Sodium-Glucose Transport Protein 2 Inhibitors Association with Euglycemic Diabetic Ketoacidosis
por: Wojtas, Caroline, et al.
Publicado: (2023) -
Euglycemic diabetic ketoacidosis by sodium glucose co-transporter inhibitors: Real but preventable concern
por: Raut, Monish S, et al.
Publicado: (2017) -
Euglycemic diabetic ketoacidosis in a patient with acute stroke taking sodium glucose co-transporter 2 inhibitor
por: Pathak, Bishnu Deep, et al.
Publicado: (2022) -
Sodium-glucose co-transporter 2 inhibitors induced euglycemic diabetic ketoacidosis within four days of initiation
por: Razok, Almurtada, et al.
Publicado: (2022) -
Euglycemic diabetic ketoacidosis: A rare but serious side effect of sodium-glucose co-transporter 2 inhibitors
por: Lakušić, Nenad, et al.
Publicado: (2022)